Pharmabiotics as an Emerging Medication for Metabolic Syndrome and Its Related Diseases
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Metabolic syndrome (MetS) is a cluster of metabolic risk factors associated with central obesity, hyperglycemia, insulin resistance, dyslipidemia and high blood pressure. In recent decades, because of the remarkable increase in both prevalence and severity, MetS and its related diseases such as cardiovascular diseases (CVDs), obesity, hypertension and diabetes have become the main global burden and challenge in strategic management involving prevention and treatment. However, currently, the preventions and treatments based on pharmaceutical interventions do not provide a solution for MetS and its related diseases. Recently, gut microbiota showed clear evidence of preventing and/or treating MetS, shedding light on treating MetS and its related diseases through a completely different approach. In this review, we will interpret the effects of current pharmaceutical drugs used in preventing and treating MetS and its related diseases to understand remaining issues of those interventions. We will explore the possibility of developing gut microbiota as pharmabiotics in a completely new medication option for treating MetS and its related diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
A comprehensive review on metabolic syndrome
Kaur, J. (2014) · Cardiology Research and Practice · doi:10.1155/2014/943162 · Cited by 1,889 · cited 7×
“The major goal of treating MetS is to reduce the risk of CVDs including raising low-density lipoprotein cholesterol (LDL-C) and reducing HDL-C, high blood pressure and abdominal fat [4].”
BackgroundInfluentialRetractedGlobal estimates of diabetes prevalence for 2013 and projections for 2035
Guariguata, L., Whiting, D. R., Hambleton, I., Beagley, J., Linnenkamp, U., & Shaw, J. E. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.11.002 · Cited by 4,642 · cited 1×
“On the other hand, the prevalence of diabetes and CVDs has been increasing more rapidly in recent decades [11,12].”
BackgroundEzetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Prevalence of and Trends in Diabetes Among Adults in the United States, 1988-2012
Menke, A., Casagrande, S., Geiss, L., & Cowie, C. C. (2015) · JAMA · doi:10.1001/jama.2015.10029 · Cited by 2,362
Microbial degradation of complex carbohydrates in the gut
Flint, H. J., Scott, K. P., Duncan, S. H., Louis, P., & Forano, E. (2012) · Gut Microbes · doi:10.4161/gmic.19897 · Cited by 2,331
Diet–microbiota interactions as moderators of human metabolism
Sonnenburg, J. L., & Bäckhed, F. (2016) · Nature · doi:10.1038/nature18846 · Cited by 2,257
Global prevalence and trends of overweight and obesity among preschool children
de Onis, M., Blössner, M., & Borghi, E. (2010) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2010.29786 · Cited by 2,182 · cited 2×
“Analyzing data from 144 countries in cross-sectional surveys, over 43 million children were estimated to be overweight and obese [20].”
BackgroundMethodThe Long-Term Stability of the Human Gut Microbiota
Faith, J. J., Guruge, J. L., Charbonneau, M., Subramanian, S., Seedorf, H., Goodman, A. L., Clemente, J. C., Knight, R., Heath, A. C., Leibel, R. L., et al. (2013) · Science · doi:10.1126/science.1237439 · Cited by 2,058
Nissen, S. E., Nicholls, S. J., Sipahi, I., Libby, P., Raichlen, J. S., Ballantyne, C. M., Davignon, J., Erbel, R., Fruchart, J. C., Tardif, J.-C., et al. (2006) · JAMA · doi:10.1001/jama.295.13.jpc60002 · Cited by 2,047
SLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801936 · Cited by 2,043
XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study
Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.155 · Cited by 1,915
Feigin, V. L., Roth, G. A., Naghavi, M., Parmar, P., Krishnamurthi, R., Chugh, S., Mensah, G. A., Norrving, B., Shiue, I., Ng, M., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30073-4 · Cited by 1,691
Gut microbiota dysbiosis contributes to the development of hypertension
Li, J., Zhao, F., Wang, Y., Chen, J., Tao, J., Tian, G., Wu, S., Liu, W., Cui, Q., Geng, B., et al. (2017) · Microbiome · doi:10.1186/s40168-016-0222-x · Cited by 1,685 · cited 4×
“an abundance of Prevotella and Klebsiella and a declination of Bifidobacterium, Butyrivibrio, Coprococcus, Faecalibacterium, Oscillibacter and Roseburia, which were enriched in healthy controls [148].”
BackgroundInfluentialMetabolic syndrome: definitions and controversies
Kassi, E., Pervanidou, P., Kaltsas, G., & Chrousos, G. (2011) · BMC Medicine · doi:10.1186/1741-7015-9-48 · Cited by 1,565 · cited 2×
“In fact, MetS is a complicated condition as presented by its definition and its utility [4,5].”
BackgroundGut Dysbiosis Is Linked to Hypertension
Yang, T., Santisteban, M. M., Rodriguez, V., Li, E., Ahmari, N., Carvajal, J. M., Zadeh, M., Gong, M., Qi, Y., Zubcevic, J., et al. (2015) · Hypertension · doi:10.1161/hypertensionaha.115.05315 · Cited by 1,478 · cited 4×
“In humans, through comprehensive metagenomic and metabolomic analyses, gut microbiota dysbiosis was described in the hypertensive phenotype [147].”
BackgroundInfluentialCurrent Understanding of Dysbiosis in Disease in Human and Animal Models
DeGruttola, A. K., Low, D., Mizoguchi, A., & Mizoguchi, E. (2016) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000750 · Cited by 1,122 · cited 2×
“The remarkable increase in the prevalence and severity of MetS throughout the world recently is stimulating efforts to explore the relationship between gut microbiota and their host metabolism, which mainly relates to the MetS epidemic [116].”
BackgroundEffects of the probiotic Bifidobacterium infantis in the maternal separation model of depression
Desbonnet, L., Garrett, L., Clarke, G., Kiely, B., Cryan, J. F., & Dinan, T. G. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.08.005 · Cited by 999 · cited 1×
“Recent studies also reported that some gut bacteria such as Lactobacillus rhamnosus and Bifidobacterium infantis reduced anxiety-like and depressive-like behaviors [155,156].”
ResultEffect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects
James, W. P. T., Caterson, I. D., Coutinho, W., Finer, N., Van Gaal, L. F., Maggioni, A. P., Torp-Pedersen, C., Sharma, A. M., Shepherd, G. M., Rode, R. A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003114 · Cited by 943 · cited 1×
“Although this drug had revealed its superiority in the treatment of exogenous obesity, the FDA asked the manufacturer to remove this drug from the market because of an elevated risk of cardiovascular issues and strokes in the studied population [108] (Table 1).”
BackgroundKhera, R., Murad, M. H., Chandar, A. K., Dulai, P. S., Wang, Z., Prokop, L. J., Loomba, R., Camilleri, M., & Singh, S. (2016) · JAMA · doi:10.1001/jama.2016.7602 · Cited by 865
Cani, P. D., Osto, M., Geurts, L., & Everard, A. (2012) · Gut Microbes · doi:10.4161/gmic.19625 · Cited by 864
The Gut Microbiome Contributes to a Substantial Proportion of the Variation in Blood Lipids
Fu, J., Bonder, M. J., Cenit, M. C., Tigchelaar, E. F., Maatman, A., Dekens, J. A. M., Brandsma, E., Marczynska, J., Imhann, F., Weersma, R. K., et al. (2015) · Circulation Research · doi:10.1161/circresaha.115.306807 · Cited by 748
Allison, D. B., Gadde, K. M., Garvey, W. T., Peterson, C. A., Schwiers, M. L., Najarian, T., Tam, P. Y., Troupin, B., & Day, W. W. (2012) · Obesity · doi:10.1038/oby.2011.330 · Cited by 711
The contributory role of gut microbiota in cardiovascular disease
Tang, W. H. W., & Hazen, S. L. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72331 · Cited by 641
The gut microbiota modulates host energy and lipid metabolism in mice
Velagapudi, V. R., Hezaveh, R., Reigstad, C. S., Gopalacharyulu, P., Yetukuri, L., Islam, S., Felin, J., Perkins, R., Borén, J., Orešič, M., et al. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m002774 · Cited by 589
Ding, X., Saxena, N. K., Lin, S., Gupta, N., & Anania, F. A. (2006) · Hepatology · doi:10.1002/hep.21006 · Cited by 557 · cited 3×
“It has been proven that Thiazolidinediones enhanced the risk of developing or worsening heart failure, developing certain types of cancer and induced bone fractures [52]; sulfonylureas caused cardiovascular mortality, while Meglitinides and Exenatide raised the incidence of benign adenomas of the thyroid and liver [53…”
BackgroundA high-fat diet is associated with endotoxemia that originates from the gut
Pendyala, S., Walker, J. M., & Holt, P. R. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.01.034 · Cited by 546
Gut microbiota and metabolic syndrome
Festi, D., Schiumerini, R., Eusebi, L. H., Marasco, G., Taddia, M., & Colecchia, A. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i43.16079 · Cited by 534 · cited 1×
“Current knowledge has supported the role of gut microbiota in the pathogenesis of two main types of diabetes mellitus [135,136].”
BackgroundKeene, D., Price, C., Shun-Shin, M. J., & Francis, D. P. (2014) · BMJ · doi:10.1136/bmj.g4379 · Cited by 513 · cited 1×
“Nicotinic acid Niacin immediate release (Niacor) or Niacin extended release (Niaspan) Decrease LDL-C, increase HDL-C in the blood, decrease TG levels by 15–25% Flushing of the face and neck along with warmth, headache, burning, sweating, chills, dizziness, stomach upset, heartburn, vomiting, diarrhea, indigestion, nau…”
Physical activity in prevention and treatment of the metabolic syndrome
Lakka, T. A., & Laaksonen, D. E. (2007) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/h06-113 · Cited by 482
Singh, S., Chang, H.-Y., Richards, T. M., Weiner, J. P., Clark, J. M., & Segal, J. B. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.2720 · Cited by 467
Use of Metformin in the Setting of Mild-to-Moderate Renal Insufficiency
Lipska, K. J., Bailey, C. J., & Inzucchi, S. E. (2011) · Diabetes Care · doi:10.2337/dc10-2361 · Cited by 432
Role of the gut microbiota in host appetite control: bacterial growth to animal feeding behaviour
Fetissov, S. O. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.150 · Cited by 403 · cited 2×
“By linking to neuropeptidergic circuitry in the hypothalamus via several bacterial products, the gut microbiota modulates human eating behavior for both short-term and long-term periods [151].”
BackgroundBunck, M. C., Diamant, M., Cornér, A., Eliasson, B., Malloy, J. L., Shaginian, R. M., Deng, W., Kendall, D. M., Taskinen, M.-R., Smith, U., et al. (2009) · Diabetes Care · doi:10.2337/dc08-1797 · Cited by 388
Ghirlanda, G., Oradei, A., Manto, A., Lippa, S., Uccioli, L., Caputo, S., Greco, A. V., & Littarru, G. P. (1993) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1993.tb03948.x · Cited by 324 · cited 6×
“The lower abundances of the class Mollicutes, families Christensenellaceae and Rikenellaceae and genus Dehalobacterium were related to a high BMI, while the family Clostridiaceae/Lachnospiraceae was related to LDL-C levels and the family Pasteurellaceae, genus Coprococcus and genus Collinsella species stercoris were s…”
BackgroundInfluentialVancampfort, D., Correll, C. U., Wampers, M., Sienaert, P., Mitchell, A. J., De Herdt, A., Probst, M., Scheewe, T. W., & De Hert, M. (2014) · Psychological Medicine · doi:10.1017/s0033291713002778 · Cited by 317 · cited 1×
“Current knowledge suggests that there is a bidirectional communication between gut microbiota and the host brain [152]; thus, the influences of gut microbiota on the metabolic-related diseases via the gut-brain axis have become more important because one of the increasing risk factors that contributes to MetS epidemic…”
BackgroundKoh, K. K., Quon, M. J., Han, S. H., Lee, Y., Kim, S. J., & Shin, E. K. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.10.053 · Cited by 229 · cited 1×
“Furthermore, the prolonged treatment or the combination of several drugs to treat these MetS and its related diseases may increase the risks of other diseases and even become life-threatening [32,33].”
BackgroundPhentermine/Topiramate for the Treatment of Obesity
Smith, S. M., Meyer, M., & Trinkley, K. E. (2013) · Annals of Pharmacotherapy · doi:10.1345/aph.1r501 · Cited by 122 · cited 1×
“PHEN/TPM has shown significant efficacy in achieving weight loss and reducing waist circumference, fasting TG and fasting glucose [106,107].”
BackgroundGarcia, S. B., da Costa Barros, L. T., Turatti, A., Martinello, F., Modiano, P., Ribeiro-Silva, A., de Oliveira Vespúcio, M. V., & Uyemura, S. A. (2006) · Cancer Letters · doi:10.1016/j.canlet.2005.09.011 · Cited by 57
Cited by
Microbiota and metabolic diseases
Pascale, A., Marchesi, N., Marelli, C., Coppola, A., Luzi, L., Govoni, S., Giustina, A., & Gazzaruso, C. (2018) · Endocrine · doi:10.1007/s12020-018-1605-5 · Cited by 423
Noormohammadi, M., Ghorbani, Z., Löber, U., Mahdavi-Roshan, M., Bartolomaeus, T. U. P., Kazemi, A., Shoaibinobarian, N., & Forslund, S. K. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2022.106614 · Cited by 40
Hatton‐Jones, K. M., du Toit, E. F., & Cox, A. J. (2022) · Neurogastroenterology & Motility · doi:10.1111/nmo.14300 · Cited by 5
Metadata
- Authors
- Nguyen, T. T. B., Jin, Y. Y., Chung, H.-J., & Hong, S.-T.
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2017-10-24
- Volume
- 22
- Issue
- 10
- Pages
- 1795
- ISSN
- 1420-3049 (ISSN-L)
- OpenAlex
- W2765962947
- Cited by
- 37
- References
- 38
- FWCI
- 0.58
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.